IP Library Granted Patent US 7,445,931
Granted Patent B2
US 7,445,931 · App. 10/529,115 · Granted Nov 4, 2008

Compositions and methods for enrichment of neural stem cells using ceramide analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,445,931
App. No.
10/529,115
Granted
Nov 4, 2008
Kind
B2
Abstract

The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.

Claims (28)

1. A method of producing a human neural cell comprising,

a) providing a pluripotent human cell; and

b) culturing the pluripotent human cell with a composition comprising a ceramide compound selected from the group consisting of N-(2-hydroxy-1-(hydroxymethyl)ethyl)-palmitoylamide (“S16”), N-(2-hydroxy-1-(hydroxymethyl)ethyl)-oleoylamide (“S18”), N,N-bis(2-hydroxyethyl)palmitoylamide (“B16”), N,N-bis(2-hydroxyethyl)oleoylamide (“B18”) N-tris(hydroxymethyl)methyl-palmitoylamide (“T16”), N-tris(hydroxymethyl)methyl-oleoylamide (“T18”), N-acetyl sphingosine (“C2-ceramide”), and N-hexanoylsphingosine (“C6-ceramide”) to produce the human neural cell.

2. The method of claim 1 , wherein the pluripotent human cell is a differentiating pluripotent human cell.

3. The method of claim 1 , comprising the intermediate step of forming an embryoid body comprising the pluripotent human cell prior to culturing a cell from the embryoid body with the ceramide compound.

4. The method of claim 3 , wherein the embryoid body is formed by culturing the pluripotent human cell with an essentially serum free medium.

5. The method of claim 4 , wherein the essentially serum free medium is a MEDII conditioned medium.

6. The method of claim 5 , comprising the additional steps of,

a) dispersing the embryoid body to an essentially single cell suspension;

b) culturing the essentially single cell suspension comprising the pluripotent human cell in an adherent culture with a composition comprising the ceramide compound.

7. The method of claim 6 , wherein the composition comprising the ceramide compound further comprises a MEDII conditioned medium.

8. The method of claim 5 wherein the MEDII conditioned medium is a Hep G2 conditioned medium.

9. The method of claim 7 , wherein the composition comprising the ceramide compound is essentially serum free.

10. A method of producing a human neural cell comprising,

a) providing a pluripotent human cell; and

b) culturing the pluripotent human cell with a composition comprising a ceramide compound of the structure

11. A method of producing a human neural cell comprising,

a) providing a pluripotent human cell; and

b) culturing the pluripotent human cell with a composition comprising a ceramide compound of the structure

12. The method of claim 1 , wherein the concentration of the ceramide compound is from approximately 0.1 μM to approximately 1000 μM.

13. The method of claim 1 , wherein the concentration of the ceramide compound is from approximately 1 μM to approximately 100 μM.

14. The method of claim 1 , wherein the concentration of the ceramide compound is from approximately 5 μM to approximately 50 μM.

15. The method of claim 1 , wherein the concentration of the ceramide compound is approximately 10 μM.

16. The method of claim 1 , wherein the duration of culturing the human pluripotent cell with the ceramide compound is from approximately 6 hours to 10 days.

17. The method of claim 1 , wherein the pluripotent human cell is selected from the group consisting of a human embryonic stem cell, a human inner cell mass (ICM)/epiblast cell, a human primitive ectoderm cell, and a human primordial germ cell.

18. The method of claim 1 , wherein the pluripotent human cell is a human embryonic stem cell.

19. The method of claim 1 , wherein the human pluripotent cell is a multipotent cell.

20. The method of claim 19 , wherein the multipotent cell is a neural precursor cell.

Assignments (7)
CONFIRMATORY LICENSE Recorded Jun 24, 2019
From: AUGUSTA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 049561/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2014
From: VIACYTE GEORGIA, INC
To: VIACYTE, INC.
Reel/Frame 033088/0083 →
CHANGE OF NAME Recorded Jun 11, 2014
From: BRESAGEN, INC
To: VIACYTE GEORGIA, INC.
Reel/Frame 033134/0130 →
CONFIRMATORY LICENSE Recorded Aug 11, 2010
From: MEDICAL COLLEGE OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024812/0865 →
CONFIRMATORY LICENSE Recorded Jul 19, 2010
From: MEDICAL COLLEGE OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024697/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2005
From: CONDIE, BRIAN G.
To: BRESAGEN, INC.
Reel/Frame 016882/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2005
From: BIEBERICH, ERHARD
To: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE
Reel/Frame 016634/0040 →